Brief: Chr. Hansen Q3 Adjusted EBIT Slightly Below Estimates
06/07/2023 07:07
Jul 6 (Reuters) - Chr. Hansen Q3 adjusted EBIT margin 27.5% vs. estimate 27.1%. * Q3 organic growth 9% vs. estimate 9.7% * Q3 adjusted EBIT EUR 92 million vs. estimate EUR 93 million * Q3 revenue EUR 335 million vs. estimate EUR 345 million * Outlook FY organic growth 9-11%
Recent news on Chr Hansen Holding A/S
See all newsJefferies sees above peer growth for Novozymes, ups to 'buy'
Brief: Combination Of Novozymes, Chr. Hansen Is Completed
Brief: Novozymes Says All Necessary Regulatory Approvals Obtained For Combination Novozymes And Chr. Hansen
European Commission clears Novozymes, Chr. Hansen merger (updated)
European Commission clears Novozymes, Chr. Hansen merger